The result of large studies conducted by international teams has confirmed that ancient DNA researchers have sequenced over 1,000 genomes in the past eight years.
The advancement of sequencing technology has had the singe biggest effect on genomics research. As it develops further, so does the scope of genomic research and applications.
Learn more about Edico Genome’s new DRAGEN Virtual Long-Read Detection (VLRD) Pipeline, that’s the first variant caller dedicated to SDs, and is designed to run with short sequence reads generated at moderate coverage.
“I Would Like to See Widespread Reimbursement of Clinical Genomic Testing as Well as Screening” – Gavin Stone
Gavin Stone is an electronics engineer who joined Edico Genome in 2013 to lead corporate development and marketing for the DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics chip to massively speed up genomic medicine.
There are wide differences in BRCA testing protocols at labs around the world. A new article surveyed 86 laboratories about their BRCA testing practices and found that all the labs differed widely in their approach.
DNAnexus launches new clinical trial solution that aims to streamline the incorporation of human genomic data into clinical trial designs.
Stephen Kingsmore and his team at Rady Children’s recently proved they could sequence a whole genome in a world record time of 19.5 hours.
A genomics startup co-founded by genetics pioneer George Church said yesterday that it seeks to lead the genomic data market by utilizing blockchain technology.
Reading the whole genetic blueprint of a fetus long before birth could become a routine procedure thanks to a new blood test.
The World Anti-Doping Agency has considered obtaining Olympic athletes’ genetic code for years, and now that could soon be becoming a reality, thanks to the decreasing cost of sequencing.
“I’d Like to See Our Understanding of at Least One More Disease Transformed by Genomics and Big Data” – Jeremy Grushcow
Combining over 15 years’ experience with pharma and life sciences businesses with a passion for participant-centric research, Jeremy Grushcow is CBO at Sequence Bio, where he saw a once-in-in a lifetime opportunity to change how we treat, prevent and understand disease.